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Summary
Background In October, 2012, Fiji introduced routine infant immunisation with a ten-valent pneumococcal conjugate 
vaccine (PCV10) using three primary doses and no booster dose (3 + 0 schedule). Data are scarce for the effect of PCV in 
the Asia and Pacific region. We aimed to evaluate the effect of PCV10 on pneumonia hospital admissions in children 
younger than 5 years and adults aged 55 years and older in Fiji, 5 years after vaccine introduction.
Methods We did a time-series analysis assessing changes in pneumonia hospital admissions at three public tertiary 
hospitals in Fiji. Four pneumonia outcomes were evaluated: all-cause pneumonia, severe or very severe pneumonia, 
hypoxic pneumonia, and radiological pneumonia. Participants aged younger than 2 months, 2–23 months, 
24–59 months, and 55 years and older were included. Data were extracted from the national hospital admission 
database according to International Classification of Diseases-tenth revision codes J10·0-18·9, J21, and J22 for all-
cause pneumonia. Medical records and chest radiographs were reviewed for the main tertiary hospital to reclassify 
hospital admissions in children aged younger than 2 years as severe or very severe, hypoxic, or radiological 
pneumonia as per WHO definitions. Time-series analyses were done using the synthetic control method and 
multiple imputation to adjust for changes in hospital usage and missing data.
Findings Between Jan 1, 2007, and Dec 31, 2017, the ratio of observed cases to expected cases for all-cause pneumonia 
was 0·92 (95% CI 0·70–1·36) for children aged younger than 2 months, 0·86 (0·74–1·00) for children aged 
2–23 months, 0·74 (0·62–0·87) for children aged 24–59 months, and 1·90 (1·53–2·31) in adults aged 55 years and 
older, 5 years after PCV10 introduction. These findings indicate a reduction in all-cause pneumonia among children 
aged 24–59 months and an increase in adults aged 55 years and older, but no change among children aged younger 
than 2 months. Among children aged 2–23 months, we observed declines of 21% (95% CI 5–35) for severe or very 
severe pneumonia, 46% (33–56) for hypoxic pneumonia, and 25% (9–38) for radiological pneumonia. Mortality 
reduced by 39% (95% CI 5–62) for all-cause pneumonia, bronchiolitis, and asthma admissions in children aged 
2–23 months.
Interpretation The introduction of PCV10 was associated with a decrease in pneumonia hospital admissions in 
children aged 2–59 months. This is the first study in a middle-income country in the Asia and Pacific region to show 
the effect of PCV on pneumonia, filling gaps in the literature on the effects of PCV10 and 3 + 0 schedules. These data 
support decision making on PCV introduction for other low-income and middle-income countries in the region.
Funding Department of Foreign Affairs and Trade of the Australian Government.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Pneumonia is a major cause of illness and death, 
especially among children younger than 5 years and adults 
aged 65 years and older in low-income and middle-income 
countries (LMICs).1 Pneumococcal pneumonia is a 
common cause of death from severe pneumonia and is a 
major contributor to severe illness; however, viral causes, 
including respiratory syncytial virus and influ enza virus 
contribute to the pneumonia burden.1 Population-based 
observational studies post-licensure of the pneumococcal 
conjugate vaccine (PCV) have shown substantial benefit 
in reducing pneumonia and invasive pneumococcal 
disease in young children.2–4 However, there is considerable 
heterogeneity in estimates of the effect of PCV on all-
cause pneumonia;5 one study assessing PCV effect in five 
countries in the Americas found that the decline in all-
cause pneumonia hospital ad mis sions ranged from no 
change to 45% in children younger than 2 years, no 
change to 23% in children aged 24–48 months, and no 
decline among adults older than 65 years.6
Since 2007, WHO has recommended that PCV be 
included in all national immunisation schedules.7 How-
ever, in most countries in the Asia and Pacific region, 
PCV is only available for purchase and is not universally 
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available in national immunsiation programmes. This 
issue is common for middle-income countries that are not 
eligible for support from Gavi, the Vaccine Alliance. Even 
with external support, govern ments require evidence of 
PCV effectiveness, but so far, data are scarce from the 
Asia and Pacific region on the effect of PCV. There is a 
particular scarcity of data for the efficacy of the ten-valent 
PCV (PCV10), and of results from countries using three 
priming doses and no booster dose (3 + 0 immunisation 
schedule),8 the most commonly used schedule in LMICs.
In October, 2012, Fiji introduced routine infant 
immunisation with PCV10 using a 3 + 0 schedule. 
We aimed to evaluate the effect of the infant PCV10 
vaccination programme on hospital admissions in Fiji 
for all-cause pneumonia in children aged younger than 
5 years and adults aged 55 years and older, and severe 
or very severe pneumonia, hypoxic pneumonia, and 
radiological pneumonia in children aged younger than 
2 years. We used the synthetic control time-series 
approach to adjust for changes in hospital admissions 
unrelated to the vaccine.
Methods
Study design and participants
We did a time-series analysis to assess changes in 
pneumonia hospital admissions at the three public 
tertiary hospitals that serve the population of Fiji (884 887 
people in 2017).9 Fiji is an upper-middle-income country 
in the Pacific and has followed the 2005 WHO Integrated 
Management of Childhood Illnesses guidelines for 
the assessment and admission of pneumonia cases 
since 2007.10
To identify cases of all-cause pneumonia and controls, 
hospital admission data for all causes of illness were 
extracted from the electronic national hospital admission 
database for children aged 0–59 months and adults aged 
55 years and older. This dataset contained admission data 
for 49% of all admissions in Fiji, excluding obstetrics, 
Research in context
Evidence before this study
We searched PubMed for evidence of the effect of the 
introduction of the ten-valent pneumococcal conjugate
vaccine (PCV10) on pneumonia using the following terms in 
combination “pneumococcal”, “conjugate vaccine”, 
“pneumonia”, “impact”, “effectiveness”, and “PCV10” between 
Jan 1, 2010, and Oct 23, 2019, with no language restrictions. 
We identified eight longitudinal observational studies that 
assessed the effect of PCV10 on pneumonia morbidity in 
children or adults or both. We selected seven of the eight studies 
with data for a minimum of 2 years post-PCV introduction and 
settings with no previous use of PCV7. All studies used hospital 
admission data with the period of follow-up post-PCV10 
introduction ranging from 2 to 5 years. One study was done in 
Zambia using a 3 + 0 schedule; one study was done in Kenya 
using a 3 + 0 schedule plus a three-dose catch-up campaign for 
infants and a two-dose catch-up campaign for children aged 
1–4 years; one study was done in Chile using a 3 + 1 schedule; 
three studies were done in Brazil using a 3 + 1 schedule; and 
one study was done in Finland using a 2 + 1 schedule. Across all 
studies, all-cause pneumonia admissions declined by between 
8–48% among young children. There were no studies 
documenting the effect of PCV10 on severe or very severe 
pneumonia or hypoxic pneumonia in children younger than 
5 years. Two studies assessed indirect protection against 
all-cause pneumonia among older unvaccinated populations: 
a study from Finland found an 18% reduction among children 
aged 7–71 months, while a study from Brazil documented a 
11–27% reduction among individuals aged 10–49 years with no 
evidence of change in older people (≥65 years).
Added value of this study
We evaluated the effect of the infant PCV10 vaccination 
programme on hospital admissions in Fiji on four pneumonia 
outcomes: all-cause pneumonia, severe or very severe 
pneumonia, hypoxic pneumonia, and radiological pneumonia 
in young children. In addition, we have evaluated indirect 
protection against all-cause pneumonia among children too 
young to be vaccinated and adults aged 55 years and older. 
To our knowledge, we report the first published data for the 
effect of PCV on pneumonia from a low-income or 
middle-income country (LMIC) in the Asia and Pacific region. 
Our results showed evidence of protection in the 24–59 month 
age group 5 years after the introduction of PCV10. There was no 
evidence of a reduction in infants younger than 2 months and 
adults aged 55 years and older, and the 2–23 month group 
showed a non-significant reduction in all-cause pneumonia, 
but significant reductions in our clinical pneumonia outcomes. 
These data build on the results from other LMICs in Africa and 
South America; however, we provide data for the first time 
from the Asia and Pacific region. A number of countires in this 
region are yet to implement PCV into their national 
immunisation schedule.
Implications of all the available evidence
The introduction of PCV10 into routine immunisation schedules 
using the traditional 3 + 0 schedule, without catch-up, has the 
potential to reduce childhood hospital admissions due to 
pneumonia in LMICs. We have shown little evidence of indirect 
protection in Fiji, 5 years after PCV10 introduction. However, 
indirect protection is likely to increase over time. To our 
knowledge, our results are the first to show the effect of PCV in a 
LMIC in the Asia and Pacific region and provide the evidence base 
to support public health decision making regarding PCV 
introduction in this region. Because the immunogenicity of 
PCV10 is similar to PCV13, it likely that either vaccine will be 
effective against childhood pneumonia, including the most 
severe outcomes.
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mental health, and conditions related to PCV except 
pneumonia or rotavirus vaccine. Data were classified 
according to primary discharge diagnosis by International 
Classification of Diseases tenth revision (ICD-10)-
Australian modifi cation codes. Re-admissions for any 
cause within 30 days were considered the same episode 
of illness and the second admission was excluded.
The Haemophilus influenzae type B vaccine was intro-
duced in 1995. PCV10 was introduced into the national 
immunisation schedule in October, 2012, without a catch-
up campaign to vaccinate older age groups. Both vaccines 
are provided as a three-dose schedule at 6, 10, and 14 weeks 
of age. National vaccine coverage estimates for three doses 
of both PCV10 and H influenzae type B vaccine were 87%, 
92%, 94%, 93%, and 98% in 2013, 2014, 2015, 2016, and 
2017, respectively.11
Ethical approval for this study was given by the Fiji 
National Health Review Ethics Committee (approval 
number FNRER 2012-28) and The University of 
Melbourne Human Ethics Research Committee (approval 
number 1238212.4).
Procedures
To obtain data for clinical pneumonia outcomes (severe 
or very severe, hypoxic, and radiological), we assessed 
hospital admissions among children aged 2–23 months 
admitted at the main tertiary referral hospital Colonial 
War Memorial Hospital (CWMH; Suva, Fiji), which 
covers approximately 60% of the Fiji population. Data 
were ascertained from 2007–17 in the patient admission 
books (according to discharge diagnosis), the national 
hospital admissions database (according to ICD-10 code), 
and autopsy books (according to a pathologist’s diagnosis). 
A list was generated of all cases in which a child aged 
2–23 months had a primary discharge diagnosis of 
pneumonia, bronchiolitis, or asthma. Subsequently, 
individual patient medical records, including a chest 
radiograph, were identified by study staff for all cases 
on the list. Data for patient demographics, clinical 
information, and deaths were extracted from the medical 
records and recorded by a paediatrician (ET). Chest radio-
graphs were re-read and re-classified by an independent 
paediatric radiologist (MdC) on the basis of the WHO 
2005 criteria.12 All clinical forms were monitored by a 
research coordinator and double-entered into EpiData, 
version 3.1.
Details on methods to identify laboratory confirmed 
pneumonia cases are included in the appendix (p 3).
Outcomes
Because there is no gold standard case definition 
for childhood pneumonia,13 we used four pneumonia 
outcomes with varying degrees of sensitivity and speci-
ficity: all-cause pneu monia (which is highly sensitive 
but not specific), and three clinical definitions based on 
WHO definitions of severe or very severe pneumonia,10 
hypoxic pneumonia (which indicates severe disease and 
is the main cause for pneumonia-associated death), 
and radiological pneumonia.12 These categories are 
not mutually exclusive. All-cause pneumonia included 
ICD-10 codes J10·0–18·9, J21, and J22. Bronchiolitis 
(ICD-10 code J21) was included because clinicians in Fiji 
code pneumonia according to Integrated Management 
of Childhood Illnesses definitions (cough and breathing 
rate, according to age) and this includes bronchiolitis. 
Severe or very severe pneumonia was based on the WHO 
2005 pneumonia case definitions10 with the addition of 
oxygen saturation of less than 90% in room air, or death 
due to pneumonia (confirmed by a pathologist at 
autopsy). Three Integrated Management of Childhood 
Illnesses danger signs are included in the WHO 2005 
definition for which data were not available in Fiji: 
inability to drink, persistent vomiting, and stridor in a 
calm child. However, stridor is most likely to be 
classified as croup in Fiji and would not be classified as 
pneumonia when taken alone. Hypoxic pneumonia was 
defined as any child with pneumonia and oxygen 
saturation of less than 90% in room air, or death due to 
pneumonia. Radiological pneumonia was defined as 
primary end point consolidation according to the WHO 
2005 standard case definition as re-read by a paediatric 
radiologist (MdC).12 Individuals with pneumonia who 
died from pneumonia before having a chest radiograph 
taken were also classified as having radiological 
pneumonia.
Statistical analysis
The pre-PCV10 period was defined as from Jan 1, 2007, to 
Sept 30, 2012, and the post-PCV10 period was defined 
as from Oct 1, 2012, to Dec 30, 2017. The annual age-
specific incidence for all-cause, severe or very severe, 
hypoxic, and radiological pneumonia was calculated as the 
number of cases within the age group divided by 100 000 
population of that age group and multiplied by 100 000, 
with exact Poisson CIs. The annual case fatality rates are 
reported for all pneumonia, bronchiolitis, and asthma 
admissions in children aged 2–23 months at CWMH. 
Case fatality rate was calculated as the number of deaths 
in hospital divided by the number of hospital cases 
multiplied by 100, with exact Poisson CIs. The incidence 
rate ratio in the pre-PCV10 period versus the post-PCV10 
period was calculated by dividing the pre-PCV10 rate by 
the post-PCV10 rate, with exact Poisson CIs.
Time-series analyses were done to quantify changes in 
the rate of the four pneumonia outcomes associated with 
the introduction of PCV10. For our primary analysis, we 
used a time-series synthetic control.6,14 This approach is 
designed to adjust for changes in pneumonia hospital 
admissions that are unrelated to the vaccine and that 
could bias estimates of vaccine effect. With the time-
series synthetic control analysis, a Poisson regression 
model was fitted to the number of pneumonia cases 
per month. As controls, we included covariates of other 
disease categories not influenced by the vaccine in the 
See Online for appendix
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model. For these controls, we grouped causes of hospital 
admissions based on ICD-10 categories (appendix p 6).
As a measure of vaccine effect, we compared observed 
cases with the estimated number of cases that would be 
expected if PCV10 had not been introduced, extrapolated 
from the model. To estimate the cases expected in the 
absence of vaccine introduction, we fitted models to 
the pneumonia data from the pre-PCV10 period, along 
with observed values of the control time-series, and 
we extrapolated the number of pneumonia hospital 
admissions in the post-PCV10 period. The ratio gave an 
estimate of the relative effect of the vaccine and the 
difference between the observed and extrapolated values 
gave an estimate of the absolute effect of the vaccine. The 
number of cumulative cases prevented was estimated by 
summing the observed and expected cases between the 
date of vaccine introduction and the indicated date. As 
a sensitivity analysis, a time-trend analysis was done 
(appendix p 4). Details on the model fitting, Bayesian 
priors, and analysis code have been published previously.6 
Several steps were taken to account for incomplete data. 
Firstly, we audited the electronic national hospital admis-
sion database between 2007–11 and 2014–15 and found 
that 89% of all-cause admissions were captured compared 
with the ward admission registers.15 We assumed that 
these missing admissions were not specific to a 
pneumonia admission but instead related to logistical 
factors pertaining to any hospital admission. For the 
clinical pneumonia outcomes, there were missing data 
for severe or very severe, hypoxic, and radiological pneu-
monia outcomes due to the patient medical records, 
chest radiograph, or oxygen saturation data being 
unavailable for review. We investigated differences 
between cases with and without missing clinical outcomes 
by comparing them for demographic and clinical 
characteristics (appendix p 7). The missing data for 
these clinical outcomes were handled using multiple 
imputation (appendix p 2).




















Annual hospital admissions 
2007 124 458 127 164 396 272/396 (69%) 62/396 (16%) 26/396 (7%)
2008 175 503 146 177 476 329/476 (69%) 65/476 (14%) 31/476 (7%)
2009 150 496 147 154 537 360/537 (67%) 72/537 (13%) 76/537 (14%)
2010 167 416 121 144 395 245/395 (62%) 49/395 (12%) 54/395 (14%)
2011 206 492 94 193 442 323/442 (73%) 89/442 (20%) 78/442 (18%)
2012 176 432 104 198 230 160/230 (70%) 50/230 (22%) 49/230 (21%)
2013 209 399 69 215 231 153/231 (66%) 39/231 (17%) 37/231 (16%)
2014 138 384 88 279 346 265/346 (77%) 64/346 (18%) 55/346 (16%)
2015 143 315 82 297 200 134/200 (67%) 30/200 (15%) 32/200 (16%)
2016 171 568 115 442 489 343/489 (70%) 59/489 (12%) 55/489 (11%)
2017 104 352 112 433 324 232/324 (72%) 30/324 (9%) 23/324 (7%)
Sex 
Female 664 (38%) 1992 (41%) 553 (46%) 1315 (49%) 1726 (43%) 1204 (43%) 265 (44%) 215 (42%)
Male 1099 (62%) 2823 (59%) 650 (54%) 1381 (51%) 2317 (57%) 1605 (57%) 338 (56%) 294 (58%)
Ethnicity
i-Taukei (Indigenous) 1390 (79%) 4111 (85%) 952 (79%) 1375 (51%) 3590 (88%) 2513 (89%) 482 (94%) 547 (90%)
Fijians of Indian descent 286 (16%) 430 (9%) 179 (15%) 1160 (43%) 313 (8%) 186 (7%) 22 (4%) 36 (6%)
Other|| 87 (5%) 274 (6%) 74 (6%) 161 (6%) 156 (4%) 116 (4%) 11 (2%) 25 (4%)
Median age (IQR), months 
unless specified
1 (0–2) 9 (6–14) 35 (28–45) 67 years (61–74) 9 (5–14) 9 (5–14) 8 (4–13) 7 (4–11)
Oximetry recorded NR NR NR NR 2253 (55%) 1833 (65%) 515 (85%) 276 (53%)
Median length of stay (IQR), 
days
6 (4–8) 4 (2–6) 3 (2–5) 6 (4–8) 4 (2–6) 4 (2–6) 6 (3–10) 5 (3–10)
Deaths 27 (2%) 74 (2%) 7 (1%) 332 (12%) 117 (3%) 117 (4%) 117 (22%) 117 (19%)
Data are n, n/N (%), or n (%) unless otherwise specified. National admissions were based on International Classification of Diseases-tenth revision codes using actual case data for all-cause pneumonia. Colonial 
War Memorial Hospital admissions were based on discharge diagnosis and clinical data. NR=not recorded. *Case definitions of severe or very severe, hypoxic, and radiological pneumonia are not mutually 
exclusive—ie, children might be classified as having multiple pneumonia outcomes; therefore the row percentages do not add up to 100% of all pneumonia, bronchiolitis, and asthma admissions. †n varies across 
variables between 2820 and 4069 due to missing data. ‡n varies across variables between 2174 and 2816 due to missing data. §n varies across variables between 482 and 609 due to missing data. ¶n varies 
across variables between 356 and 518 due to missing data. ||Other included ethnicities of Pacific Islands other than Fiji, European, and Chinese. 
Table 1: Characteristics of pneumonia hospital admissions in Fiji, 2007–17 
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Data were analysed using STATA, version 14 and R, 
version 3.3.
Role of the funding source
The Fiji Health Sector Support Program, which imple-
mented the bilateral health programme on behalf of the 
Australian Government (a study funder), contributed to 
the conception and design of the study. The funders of 
the study had no role in data collection, data analysis, 
data interpretation, or in the decision to submit for 
publication. KJ was an employee of the funder and had a 
role in the writing of the report. RR had full access to all 
the data in the study and FMR had final responsibility for 
the decision to submit for publication.
Results
Between Jan 1, 2007, and Dec 31, 2017, there were 
14 386 national hospital admissions due to all-cause 
pneumonia and 10 479 of these occurred within the age 
groups relevant for this study (<2 months, 2–23 months, 
24–59 months, and ≥55 years). Summary data for nati-
onal and CWMH admissions are shown in table 1, 
monthly case numbers are shown in appendix p 8, 
and annual incidence is shown in appendix p 11. Among 
the 2–23 month age group admitted to CWMH, there 
were 4069 hospital admissions due to pneumonia, bron-
chiolitis, or asthma. Of these, 494 (12%) were missing 
clinical data required to assign severity status, 1816 (45%) 
were missing hypoxia status, and 1765 (43%) were missing 
radiological pneumonia status (appendix p 7). After 
adjustments for the missing data, the mean number of 
cases classified as severe or very severe pneumonia was 
3181, as hypoxic pneumonia was 937, and as radiological 
pneumonia was 846.
We observed a 39% reduction in case fatality rates for 
all pneumonia, bronchiolitis, and asthma admissions 
in children aged 2–23 months at CWMH between the 
pre-PCV10 and the post-PCV10 period (incidence rate 
ratio 0·61, 95% CI 0·38–0·95; p=0·021; appendix p 12).
Our analysis on all-cause pneumonia associated with 
the introduction of PCV10 is shown in the figure and 
table 2. The ratio of observed cases to expected cases for 
all-cause pneumonia was 0·86 (95% CI 0·74–1·00) 
5 years post-PCV10 introduction among children aged 
2–23 months and 0·74 (0·62–0·87) among children aged 
24–59 months (table 2). There was no evidence of a 
reduction in pneumonia hospital admissions among the 
children aged younger than 2 months and adults aged 
55 years and older post-PCV10. For the 55 years and older 
age group, there was an increase 5 years post-PCV10 
(ratio of observed to expected 1·90 [95% CI 1·53–2·31]; 
table 2).
The estimated cumulative number of cases prevented 
following PCV10 introduction is shown in the appendix 
(pp 14, 17). The largest numbers of all-cause pneumonia 
hospital admissions were prevented in the 2–23 month age 
group. In this age group, 315 (95% CI –22 to 686) hospital 
admissions were estimated to have been prevented for 
all-cause pneumonia within 5 years of vaccine introduction. 
Among all three age groups of children younger than 
5 years, we found substantial uncertainty around the 
estimates of cases prevented. More details on the relation-
ship between the control variables and pneumonia are 
described in the appendix (p 4).
Regarding our clinical pneumonia outcomes associated 
with introduction of PCV10, we found a 21% (95% CI 5–35) 
reduction in severe or very severe pneumonia, 46% (33–56) 
reduction in hypoxic pneumonia, and 25% (9–38) reduc-
tion in radiological pneumonia among children aged 
2–23 months, relative to control diseases and using 
pneumonia data imputed to correct for missing data for 
case definitions (figure, table 2, appendix pp 15–16). 
Credible intervals for these estimates were wide due to the 
small numbers of cases (monthly case numbers are shown 
on appendix p 8) and unexplained variability in the data. 
The rolling rate ratio decreased to less than 1 before the 
vaccine was introduced, which indicates that some of the 
reduction might be due to other factors (appendix p 16). 
How well the control variables correlated with outcome 
variable pneumonia is described in the appendix (p 4).
There was a 75% decrease (95% CI 18–94; p=0·0041) in 
bacteraemic pneumococcal pneumonia among children 
younger than 5 years and no change among adults aged 
55 years and older (ratio of observed to expected 1·26 
Figure: Times-series plots for all-cause pneumonia, by age group
The blue line indicates actual cases. The red dotted line indicates the fitted model. The white dotted line indicates 
extrapolated values based on synthetic control model. Grey shading indicates the 95% CI at timepoints after 
introduction of the ten-valent pneumococcal conjugate vaccine in October, 2012. <2 months (A), 2–23 months 





















































e96 www.thelancet.com/lancetgh   Vol 9   January 2021
[95% CI 0·40–4·63]; p=0·69) in the post-PCV10 period 
(2013–17) versus pre-PCV10 period (2007–11; appendix 
p 13). Full results are in the appendix (p 6).
We evaluated the sensitivity of the results to the 
modelling approach, by comparing simple trend adjust-
ments with the synthetic control model and by evaluating 
the estimated effect when different control variables 
were used (appendix p 4). The results were robust for 
those aged 55 years and older whereas, for the 
24–59 month age group, the results were sensitive to 
the modelling approach used, and alternative models 
gave different estimates: in the time-trend analysis, 
the estimates of the rate ratio were closer to 1 among the 
2–23 month age group for all outcomes, and none of 
the clinical pneumonia outcomes showed a significant 
change over time (table 2).
Discussion
To our knowledge, this study represents the first 
evaluation of the effect of PCV10 on pneumonia from a 
LMIC in the Asia and Pacific region, and provides 
data for the effect of PCV10 on pneumonia hospital 
admissions, of which there is a paucity, in particular with 
use of a 3 + 0 schedule. We evaluated several clinically 
relevant pneumonia outcomes. We found evidence of 
protection in the 24–59 month age groups with all-cause 
pneumonia and in the 2–23 month age groups with 
severe or very severe, hypoxic, or radioligical pnuemonia. 
The ratio of observed cases to expected cases for all-cause 
pneumonia was 0·86 (95% CI 0·74–1·00) among 
children aged 2–23 months and we found no evidence of 
indirect effects in the infants too young to be vaccinated 
(<2 months) or older people (≥55 years). Mortality 
reduced by 39% among children aged 2–23 months 
who were admitted to CWMH with all-cause pneumonia, 
bronchiolitis, and asthma.
Our results showed that hospital admissions for severe 
or very severe, hypoxic, and radiological pneumonia in 
children aged 2–23 months reduced by 14–46% after 
introduction of PCV10 in Fiji. Bacteraemic pneumococcal 
pneumonia also reduced, although total cases were few. 
Hospital admissions for non-pneumonia causes did not 
change suggesting that the decrease was unlikely to be 
due to changes in clinical practice or health-seeking 
behaviour. These findings are largely in line with 
patterns observed in a study of five countries in the 
Americas.6 Observational studies in The Gambia and 
Brazil estimated a 23–29% decline in radiological 
pneumonia among children younger than 2 years.3,16 An 
inherent problem with undertaking PCV effect studies 
on pneumonia is the absence of a gold standard case 
definition to capture all cases of pneumococcal pneu-
monia. Because pneumococcal pneumonia has been 
estimated to account for 50% of all child pneumonia 
deaths,17 the effect of PCV is expected to be higher for the 
more severe outcomes, including hypoxic pneumonia, 
which is more likely to be pneumococcal, compared with 
the less specific outcomes of all-cause and severe or very 
severe pneumonia. Our results support this assumption, 
finding greater decreases in the incidence of hypoxic 
pneumonia than severe or very severe pneumonia and 
all-cause pneumonia.
In the 2–23 month age group, we found the ratio of 
observed cases to expected cases was 0·86 (95% CI 
0·74–1·00) in all-cause pneumonia, but we had less 
certainty regarding this finding as the lower band of the 
95% CI was one, and the variability in the data made it 
difficult to accurately assess changes associated with the 
vaccine. This variability is due in part to epidemic 
variability in pneumonia hospital admissions during the 
post-PCV10 period, which was not well explained by the 
model. An epidemic of pneumonia of unknown cause in 
2014–15 and 2016–2017 particularly challenged the analysis 
in this age group. However, for many age groups, the 
control variables did not adequately adjust for the 
epidemic variations in the data, so the analyses were 
effectively comparing incidence before and after vaccine 
introduction. Other studies have found similar estimates 
of effect to ours. Two studies from Brazil and one from 
Zambia found that changes in all-cause pneumonia 
hospital admissions among children younger than 5 years 
varied between a 2% increase and 38% decrease following 
the introduction of PCV10.16,18,19
Mortality reduced by 39% among children aged 
2–23 months who were admitted to CWMH with all-cause 
pneumonia, bronchiolitis, and asthma. Few studies have 








<2 months 2–23 months 24–59 months ≥55 years
Synthetic control 0·92 (0·70–1·36) 0·86 (0·74–1·00) 0·74 (0·62–0·87) 1·90 (1·53–2·31) 0·79 (0·65–0·95) 0·54 (0·44–0·67) 0·75 (0·62–0·91)
Time trend 0·83 (0·53–1·27) 0·94 (0·76–1·16) 0·98 (0·70–1·36) 2·51 (1·66–3·54) 1·20 (0·78–1·84) 0·80 (0·51–1·25) 0·89 (0·56–1·42)
Data are the ratio of observed to expected cases (95% CI). Expected cases were those projected to occur if time trends were to continue; thus, a ratio of less than 1 indicates a 
decrease, and a ratio of more than 1 indicates an increase. Data were estimated using the synthetic control and time-trend method with imputed data (multiple imputation 
was only done for severe or very severe, hypoxic, and radiological pneumonia outcomes) in Fiji by PCV period. The pre-PCV10 period was defined as Jan 1, 2007, to 
Sept 30, 2012, and the post-PCV10 was defined as Oct 1, 2012, to Dec 31, 2017. PCV=pneumococcal conjugate vaccine.
Table 2: Ratio of the observed cases to the expected cases in pneumonia hospital admissions by age group
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documented the effect of PCV on pneumonia mortality, 
but the effect on hypoxia (a potential precursor to mortality) 
provides supportive evidence of mortality risk. Previous 
studies showed that, following PCV13 introduction, 
hypoxic pneumonia decreased by 47% among Malawian 
children younger than 5 years and 57–72% among 
Gambian children aged 2–23 months.3,4 All-cause mortality 
reduced by 16–36% in studies from Chile, The Gambia, 
Malawi, and Nicaragua.20–22 Among Moroccan children 
younger than 5 years, mortality from respiratory causes 
decreased by 28% and in those younger than 1 year, it 
decreased by 30% after the introduction of PCV13.23
Our estimates on the effect of PCV10 on severe or very 
severe pneumonia, hypoxic pneumonia, and radiological 
pneumonia show a variance according to whether results 
were adjusted for missing data by imputation. The 
sensitivity analyses without imputed data assumed that if 
the data were missing, then the outcome was not present. 
This method is likely to have underestimated case 
numbers, with a possible bias towards the null in 
estimating PCV10 effect because a substantial proportion 
of cases were missing classification data (13% were 
missing severity results, 54% were missing hypoxia 
results, and 23% were missing radiology results), with a 
greater proportion of missing data in the pre-PCV10 
period compared with the post-PCV10 period. Multiple 
imputation addresses this potential bias by replacing 
missing data with imputed values modelled using 
clinical information, thus including all cases in the 
analysis. Because the missing data were associated with 
severity, we adjusted for missing data by including 
clinical variables in the multiple imputation model. 
Therefore, we consider the multiple imputation results 
to be a more valid estimate of the true vaccine effect.
Indirect effects were not evident in infants aged 
younger than 2 months and adults aged 55 years 
and older. The exact contribution of pneumococci to 
pneumonia in very young infants is unknown; however, 
studies suggest that Streptococcus pneumoniae probably 
causes about 25% of neonatal pneumonia cases in 
LMICs24 and 66% of acute lower respiratory infections in 
children younger than 5 years globally.25 In a separate 
study in Fiji looking at pneumococcal carriage in infants 
aged 5–8 weeks pre-PCV10 introduction, we found that 
10% of serotypes carried were PCV10 types.26 Since 
pneumococcal carriage is a precursor for invasive 
disease, PCV10 serotypes might contribute little to very 
young infant pneumococcal infection in this setting.
The reason for the increase in cases of pneumonia in 
the 55 years and older age group is unknown. Other 
studies show heterogeneous results for indirect effect on 
pneumonia among older people (≥65 years), with the 
majority documenting no effect.27 In Scotland, the rates 
of pneumonia hospital admissions were also found to 
have increased among older people after the introduction 
of PCV13.28 In Fiji, we found no change in bacteraemic 
pneumococcal pneumonia, suggesting the increase was 
due to another cause and not serotype replacement. We 
also found that rates of all-cause hospital admissions 
increased for the 55 years and older age group, which 
suggests this change was not specific to pneumonia. In a 
separate analysis on the effect of PCV10 on invasive 
disease, we found an increase in ICD-10 coded all-cause 
sepsis in this age group in the post-PCV10 period 
(unpublished). Further virological and microbiological 
data are required to understand this finding, but 
Staphylococcus aureus might contribute to this increase in 
pneumonia hospital admissions in this age group and 
needs further investigation.
In addition to the weaknesses already highlighted, 
our study has limitations that are common to other 
retrospective observational studies that evaluate vaccine 
effects. First, the use of hospital admission data is likely 
to be subject to incomplete reporting that might vary 
during the period of the study. We quantified the degree 
of under-reporting of pneumonia cases through an 
audit of the national hospital admission database and 
found that 89% of admissions at the tertiary hospitals 
were captured when compared with the hospital ward 
registers.15 Second, the decrease in childhood pneumonia 
hospital admissions might also be due to other factors 
unrelated to PCV10, including changes in access to 
care, admission practice, population changes, and other 
health interventions. This limitation is inherent to all 
observational studies and therefore causation cannot be 
implied generally. In this study, we used the novel 
synthetic control method to adjust for changes in 
admissions (eg, due to changes in reporting, access to 
care, among others) that are unrelated to PCV10 
introduction, and therefore used the time-trend method 
as a sensitivity analysis. Variation in the interpretation of 
chest radiographs is a possibility that we minimised by 
using a single senior consultant radiologist.
In conclusion, we found a temporal association of 
PCV10’s effects on hospitalised pneumonia in children 
aged 24–59 months, and decreases in clinical pneumonia 
outcomes in children aged 2–23 months. These results 
were consistent with our previous findings showing a 
reduction in vaccine-type pneumococcal carriage in young 
children 3 years after the introduction of PCV10 in Fiji.26 
These results provide supportive evidence of the probable 
benefits of PCV10 in reducing pneumonia in children in 
Fiji. Our findings are likely to be helpful for decision 
making regarding PCV introduction for other LMICs in 
the Asia and Pacific region. In addition, the quantification 
of the PCV effect could provide an opportunity for 
economic studies to compare relative benefits of PCV with 
other interventions to reduce child mortality.
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